Henry Schein (NASDAQ:HSIC) and Lifevantage (NASDAQ:LFVN) Financial Review

Lifevantage (NASDAQ:LFVN) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Lifevantage and Henry Schein, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0	1	2	0	2.67
Henry Schein	1	8	5	0	2.29

Lifevantage presently has a consensus target price of $23.50, indicating a potential upside of 259.33%. Henry Schein has a consensus target price of $76.08, indicating a potential upside of 2.17%. Given Lifevantage’s stronger consensus rating and higher possible upside, equities analysts clearly believe Lifevantage is more favorable than Henry Schein.

Profitability

This table compares Lifevantage and Henry Schein’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifevantage	4.29%	33.75%	15.26%
Henry Schein	3.05%	14.36%	5.52%

Earnings and Valuation

This table compares Lifevantage and Henry Schein”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.88 million	0.36	$9.81 million	$0.77	8.49
Henry Schein	$12.94 billion	0.68	$390.00 million	$3.16	23.56

Henry Schein has higher revenue and earnings than Lifevantage. Lifevantage is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lifevantage has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Institutional and Insider Ownership

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 1.1% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Henry Schein beats Lifevantage on 8 of the 14 factors compared between the two stocks.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.